ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.

Background: Patient outcomes were assessed based on a pre-biopsy ExoDx Prostate (EPI) score at 2.5 years of the 5-year follow-up of ongoing prostate biopsy Decision Impact Trial of the ExoDx Prostate (IntelliScore).

Methods: Prospective, blinded, randomized, multisite clinical utility study was conducted from June 2017 to May 2018 (NCT03235687).

Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.

Purpose: It is unknown whether compliance with recommended monitoring tests during observation of localized prostate cancer has changed over time.

Materials And Methods: We performed a retrospective cohort study of Medicare beneficiaries diagnosed with low- or intermediate-risk prostate cancer in 2004-2016 who were initially managed with observation for a minimum of 12 months. The primary objective was to examine rates of PSA testing, prostate biopsy, and prostate MRI.